The CXC chemokine receptor 4 (CXCR4) is a widely expressed G protein-coupled receptor implicated in several diseases. In cancer, an increased number of surface CXCR4 receptors, in parallel with aberrant signaling, have been reported to influence several aspects of malignancy progression. CXCR4 activation by the specific ligand C-X-C motif chemokine 12 (CXCL12) induces several intracellular signaling pathways that have been selectively related to malignancy depending on the tissue or cell type. We developed a panel of CXCR4 screening assays investigating Gα i -mediated cyclic adenosine monophosphate modulation, β-arrestin recruitment, and receptor internalization. All of the assays were set up in recombinant cells and were used to test four reported CXCR4 antagonists. Consequently, a set of hit compounds, deriving from a screening campaign of a 30,000-small-molecule internal library, was profiled with the different assays. We identified several compounds showing a pathway-selective activity: antagonists on a Gα i -dependent pathway; antagonists on both the β-arrestin and Gα i -dependent pathways, some of which induce receptor internalization; and compounds with an antagonist behavior in all of the readouts. The identified biased antagonists induce different functional states on CXCR4 and preferentially affect specific downstream responses from the activated receptor, thus providing an improved therapeutic profile for correction of CXCR4 abnormal signaling.
Introduction
The CXC chemokine receptor 4 (CXCR4) is a G proteincoupled receptor (GPCR) that exerts its biological effect by binding the chemokine CXCL12, also known as stromal cell-derived factor 1α (SDF-1α). 1 Activation of CXCR4 by CXCL12 is known to play an important role in cell migration and differentiation, thus affecting embryonic development, hematopoiesis, immunity, and vascularization, 2 and in addition, CXCR4 is a coreceptor for HIV cell entry. 3 Heterozygous mutations in the CXCR4 gene lead to a rare combined immunodeficiency known as WHIM (warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis) syndrome. 4 CXCL12 and CXCR4 have been implicated in CNS disorders such as ischemic injuries and multiple sclerosis. 5 CXCR4 enhanced expression and aberrant downstream signaling are involved in several cancers. For instance, the chemokine CXCL12 and its receptor, CXCR4, are overexpressed in acute and chronic leukemia and in a number of solid primary and metastatic human cancers, including brain tumors and breast, pancreatic, prostate, and ovarian cancer, 2 where it is involved in tumor growth, vascularization, and metastasis. The role of CXCR4 activity and its implications for glioblastoma pathogenesis have been recently reviewed. 6 These data indicate that CXCR4 is a relevant therapeutic target for cancer treatment. 7 CXCR4 activation leads to a number of intracellular events occurring through both G protein-dependent and -independent signaling pathways. CXCR4 in particular can couple to multiple Gα isoforms. 1, 8 Investigation of the aberrant events of CXCR4 signaling in cancer has provided evidence that sustained suppression of cyclic adenosine monophosphate (cAMP), occurring on Gα i -dependent signaling, affects brain tumor cell growth. 9 Pertussis toxin treatment inhibits CXCL12-induced actin polymerization and cell migration in metastatic breast cancer cells, thus confirming the involvement of Gα i signaling in tumor invasion. 10 Other studies indicated that throughout cerebellar development, CXCL12 induces calcium flux and chemotaxis in a pertussis toxin-dependent fashion, suggesting that this response of CXCR4 is also mediated by Gα i . 11 Experimental evidence of CXCR4-Gα 12/13 coupling has also been published. 8 The activated CXCR4 is subjected to receptor desensitization following recruitment of β-arrestin, which targets the receptor to clathrin-coated pits for endocytosis. 12 Besides its role as a scaffold protein, β-arrestin has also been shown to be an effector molecule for the mitogen-activated protein kinase (MAPK) pathway. 13, 14 This β-arrestin-mediated signal transduction has been proposed to play a role in the development of cancer metastasis. For example, β-arrestin functions as a mediator of CXCL12-induced chemotaxis via the ASK1-p38 MAPK pathway in neuroectodermal cancer cells. 15 The CXCR4-CXCL12 axis exhibits a complex altered signaling in several cancers consisting of a greater overlap between G protein-dependent and G protein-independent signals. 8 In this study, we focused our efforts on the development of a panel of screening assays for the profiling of compound activity on the different CXCR4 signaling pathways. These assays include the evaluation of Gα i -mediated cAMP modulation, G protein-independent β-arrestin recruitment, and receptor internalization.
In the development of these assays, we profiled a set of four CXCR4 antagonists (AMD3100, T140, FC131, and CTCE-9908) [16] [17] [18] [19] [20] and phorbol 12-myristate 13-acetate (PMA), a potent protein kinase C (PKC) activator. 21 A screening campaign was subsequently performed with a 30,000-compound library (constituted of commercial and proprietary compounds selected to maximize chemical diversity); a homogeneous time-resolved fluorescence (HTRF) assay to measure Gα i -mediated changes in intracellular cAMP levels was used as a primary screen, and β-arrestin recruitment and receptor internalization as secondary assays. The profiling of hit compounds with the different assay technologies indicated that some compounds were functionally selective for certain CXCR4 signaling pathways.
Materials and Methods

Reagents
CXCL12 was purchased from Bachem AG (Bubendorf, Switzerland). AMD3100 and PMA were obtained from Sigma-Aldrich (St. Louis, MO, USA). FC-131, T140, and CTCE-9908 were all purchased from Mimotopes (Clayton, Australia). Iso-butyl-methyl xanthine (IBMX), forskolin, and bovine serum antigen (BSA) were acquired from Sigma-Aldrich.
Cell Culture
CHO-K1 cells were purchased from the Interlab Cell Line Collection (Genoa, Italy) and were grown in Ham's F12 medium supplemented with 10% fetal bovine serum, 1% GlutaMax™, and 1% Pen Strep (Life Technologies, Carlsbad, CA, USA) in a humidified incubator at 37°C and 5% CO 2 .
U2OS cells (European Collection of Cell Cultures/Health Protection Agency Culture Collections, Salisbury, UK) were grown in McCoy's 5A medium (Life Technologies) supplemented with 10% fetal bovine serum, 0.5% GlutaMax™, and 1% Pen Strep in a humidified incubator at 37°C and 5% CO 2 .
A primary glioblastoma cell line from a tumor-recurrent glioblastoma patient (GBMR16) was obtained from the IRCCS Besta Hospital in Milan, Italy. Cells were cultured with neurosphere (NS)-forming medium, which was prepared as follows: DMEM/F12 1:1 (Life Technologies), B27 serum-free supplement (Life Technologies), 1% Pen Strep, 250 µg/ml Fungizone® (Life Technologies), 20 ng/ml epidermal growth factor (EGF), and 20 ng/ml basic fibroblast growth factor (bFGF) (the latter two from Peprotech, Rocky Hill, NJ, USA).
Generation of Recombinant Cell Lines
CHO-CXCR4 Cell Line. The pcDNA3.1-Hygro(-)CXCR4 plasmid was generated by cloning the human CXCR4 cDNA with a NotI (Life Technologies) restriction digestion from the pCMV6-XL5-CXCR4 plasmid (OriGene Technologies, Rockville, MD, USA) into the pcDNA3.1-Hygro(-) (Life Technologies) expression plasmid. Transfection of CHO-K1 cells was then performed using FuGene6® (Roche Applied Science, Basel, Switzerland) according to the manufacturer's instructions. Selection of recombinant cells was carried out using 1.8 mg/ml Hygromycin (Life Technologies). Recombinant cell pools expressing surface CXCR4 receptor were identified by fluorescence-activated cell sorting (see protocol in this article). Single-cell clones were obtained by a dilution-cloning method.
The clones were then tested for a functional cAMP response (see protocol below) in the presence of 5 µM forskolin, 500 µM IBMX, and 10 or 100 nM CXCL12. The CHO-CXCR4 D13 clone was used for assay development and screening. Ready-to-use frozen batches of CHO-CXCR4 recombinant and wild-type cells were prepared and used for each run of screening.
U2OS-SNAP-CXCR4 Cell Line. The pSEMS1-SigER-SNAPm-CXCR4 plasmid, containing the SNAP-tag fused to the N-terminus of human CXCR4, was purchased from Covalys Biosciences AG (D1057-1, Witterswil, Switzerland; now acquired by New England Biolabs, Ipswich, MA, USA). Transfection of U2OS cells with the plasmid was performed using FuGene6® (Roche) according to the manufacturer's instructions. Chemical selection of stable recombinant cells was carried out using 0.5 mg/ml G418 (Life Technologies). Recombinant cell pools expressing surface SNAP-CXCR4 receptor were identified by fluorescence-activated cell sorting (see protocol below). Singlecell clones were obtained by a dilution-cloning method.
Labeling with the cell-impermeable SNAP-Surface 549 substrate (New England Biolabs) and subsequent addition of 100 nM CXCL12 allowed the selection of the bestresponding clones by evaluating the internalized receptor using the BDPathway435 high-content cell analyzer (BD Biosciences, San Jose, CA, USA) (see protocol below).
Fluorescence-Activated Cell Sorting (FACS) Analysis of CXCR4 Membrane Expression
To select a positive cell pool during CHO-CXCR4 recombinant cell-line generation and to investigate CXCR4 surface expression on glioblastoma cell lines, resuspended cells were first labeled with 0.2 µl/sample mouse antihuman CXCR4 that was phycoerythrin (PE) conjugated (BD Biosciences), followed by fluorescence-activated cell sorting, using the BD FACSAria TM system (BD Biosciences). Nonspecific binding of primary antibodies to cell surface antigen was estimated with 0.2 µl/sample PE mouse IgG2a, κ isotype control antibody (BD Biosciences).
For the selection of a positive cell pool during U2OS SNAP-CXCR4 recombinant cell-line generation, cells were first labeled with nonpermeable SNAP-Surface 549 substrate (New England Biolabs) at the concentration of 2 µM, followed by fluorescence-activated cell sorting with the BD FACSAria system.
cAMP HTRF® Assay
Changes in intracellular cAMP concentrations were measured with an HTRF ® assay (cAMP Dynamic 2 Kit, Cisbio Bioassays, Codolet, France), according to the manufacturer's protocol.
CHO-CXCR4 D13 ready-to-use frozen cells were thawed and resuspended in Dulbecco's phosphate buffered saline (Lonza, Basel, Switzerland) with 1 mM IBMX to 1.2×10 6 cells/ml. 384-well, low-volume microplates (Greiner Bio-One GmbH, Frickenhausen, Germany) were prepared containing 6000 cells in 5 µl per well. Cell treatment was performed in assay buffer containing phosphatebuffered saline (PBS) 0.2% BSA. The cells were pre-incubated for 15 min at room temperature with 2.5 µl of a fourfold-concentrated compound solution at single concentration or in a concentration-response titration (1% final DMSO concentration), with 10 µM AMD3100 (final concentration) for the reference-compound wells, or with DMSO only for negative-and positive-control wells. Subsequently, 2.5 µl of a CXCL12-forskolin solution at fourfold the respective EC 80 concentrations (ranging from 0.8 and 2 nM and 0.4 and 2 µM, respectively) were added to each well except for positive-control wells, in which only forskolin was added. After 45 min, 5 µl of the HTRF detection reagents (anti cAMP-Cryptate and cAMP-d2) were added to the cells according to the kit instructions. All the pipetting steps were performed by a Freedom Evo liquid-handling device (TECAN, Männendorf, Switzerland). After 1 h of incubation at room temperature, the timeresolved fluorescence was read with an AnalystGT microplate reader (Molecular Devices, Sunnyvale, CA, USA) using the following filter settings: top dichroic 400, excitation 337 nm, emission 665 nm and 620 nm (for acceptor and donor signals, respectively), integration time 400 µs, and delay time 50 µs.
The HTRF signal ratio was calculated according to the following formula: 665 / 620 ratio = Fluorescence intensity at 665 nm 0 Fluorescence i 4 × 1 n ntensity at 620 nm Data were normalized between forskolin-treated cells (0%) and CXCL12-and forskolin-treated cells (100%). The activity threshold was set to 50%.
Interference on fluorescent signal was considered unacceptable, and the related compound was discarded when the emission at 620 nm was lower than 80% or higher than 120% with respect to the negative control mean.
A similar protocol was followed for the cAMP counterassay on CHO-K1 wild-type frozen cells. In this case, cells were preincubated with the compound for 15 min at room temperature and then treated with forskolin at a concentration equal to the EC 20 (to mimic the effect of the agonist) for 45 min. Forskolin alone at the EC 20 concentration represented the stimulation for negative-control wells, whereas forskolin at the EC 80 concentration was applied in positive-control wells. The HTRF cAMP measurement was performed as previously described. Data were normalized on forskolin-treated cells at the EC 80 (0%) and the EC 20 concentrations (100%). Compounds inhibiting the HTRF signal more than 30% were considered unspecific.
PathHunter™ Enzyme-Fragment Complementation (EFC) Assay
The PathHunter® protein complementation assay measuring β-arrestin recruitment by activated CXCR4 (#93-0001, DiscoveRX Corporation, Fremont, CA, USA) was performed according to the manufacturer's protocol. The assay was conducted in 384-well assay plates (Perkin Elmer, Waltham, MA, USA) in a final volume of 25 µl/ well and a final DMSO concentration of 1%. EasyScreen™ β-arrestin CXCR4 cells (DiscoveRX) were seeded at a concentration of 5000 in 20 µl per well. After 24 h incubation at 37°C (5% CO 2 and 95% relative humidity), cells were serum starved for 3 h by replacing culture medium with OptiMEM (Life Technologies). In the antagonist assay, 2.5 µl of a 10-fold-concentrated compound solution were added either at single concentration or in a concentration-response titration. 10 µM final concentration of AMD3100 and DMSO was added to positive-and negative-control wells, respectively. After 60 min at 37°C, 2.5 µl of CXCL12 at a concentration corresponding to 10-fold the EC 80 was added to the compounds, and the incubation continued at 37°C for other 90 min. For data normalization, the controls represented by CXCL12 at its EC 80 concentration (100%) and CXCL12 plus an AMD3100 reference antagonist (0%) were used. The activity threshold was set to 50%. In the agonist assay, 5 ml/well of a fivefold-concentrated compound solution was added in the absence of CXCL12. CXCL12 at its maximum efficacy concentration (100%) and DMSO alone (0%) were considered the positive-and negative-control wells, respectively. Chemiluminescent PathHunter® Detection reagent (12 µl/well) was then added, and the incubation continued at room temperature for 60 min. The chemiluminescent signal was measured using a Mithras LB940 microplate reader (Berthold Technologies GmbH &Co. KG, Bad Wilbad, Germany), using a counting time of 1 s/ well. The robustness of data from every single screening run was monitored by Z' and Signal Window calculation. 22 Plates with Z' < 0.4 and Signal Window < 2 were discarded and repeated.
β-Galactosidase Counterassay
A volume of 5 µl of a 4 nM β-galactosidase solution produced from Escherichia coli cells (G4155, Sigma) was added to 20 µl assay volume/well containing the tested compound at a final concentration of 10 µM or only medium in negative-control wells. The reaction was carried out in the same medium supplied for the PathHunter™ β-arrestin translocation assay (93-0001, DiscoveRX). Immediately before reading, 12 µl/well of detection reagent (PathHunter™, DiscoveRX) was added. The bioluminescent signal was then measured as above with a Berthold Mithras luminometer.
High-Content Screening (HCS) Internalization Assay
U2OS SNAP-CXCR4 B5 cells were seeded at a concentration of 3000 cells/well in 384-well black, clear-bottom imaging plates (BD Biosciences) and were incubated for 24 h at 37°C, 5% CO 2 , 95% relative humidity. The culture medium was replaced with 10 µl/well of 2 µM SNAP-Surface 549 substrate in assay buffer (HBSS-Hepes, pH 7.4 with 1% BSA), and the plate was incubated with shaking for 10 min at 37°C in the dark. The plate was washed three times with an ELx405 microplate washer (BioTek, Winooski, VT, USA), and 15 µl of assay buffer was added to each well together with 15 µl of a threefold-concentrated compound solution with a 1% final DMSO concentration followed by 10 min incubation at room temperature (RT). For each compound, 10 concentrations in half-log interval were tested. For the antagonist assay, 15 µl of threefoldconcentrated CXCL12 solution at EC 80 concentration (15 nM) was added to each well except to positive-control wells. Cells stimulated with DMSO or with CXCL12 at its EC 80 represented the positive (0%) and negative (100%) controls, respectively. For the agonist assay, the compound was added at the desired concentration in the absence of CXCL12, data were normalized on DMSO-negative control wells (0%), and CXCL12-treated cells represented the positive control (100%). The cells were incubated with compounds for 1 h at 37°C. The plate was then washed as above, and cells were fixed at RT with 4% (w/v) paraformaldehyde-sucrose in PBS. Nuclei were counterstained with 50 µg/ml Hoechst 33342 (Life Technologies), and cell cytoplasm with 0.125 µg/ml HCS Cell Mask Deep Red Stain (Life Technologies). All the pipetting steps were performed by a Freedom Evo liquid-handling device (TECAN). Fluorometric images were acquired with a BDPathway435 high-content cell analyzer (BD Biosciences). Images of Hoechst (ex/em 377/435 nm), SNAP-Surface 549 (ex/em 543/593 nm), and HCS Cell Mask (ex/em 628/692 nm) were captured with four frames per well and analyzed using the Attovision 1.6 analysis package (BD Biosciences). The acquired images were segmented to define the regions of interest (ROIs) based on HCS Cell Mask staining, and the granularity of the SNAP-549 signal in the segmented regions was used as a primary readout parameter. In addition, the ROI number and the SNAP-549 intensity values were used as control parameters to assess unspecific compound effects; a toxicity flag was applied when less than 70% of the ROI number, as compared to ROIs of the control wells, was found in both replicates of the two highest compound concentrations tested (30 and 10 µM). An interference flag was applied when the intensity values were lower than 70% or higher than 130% with respect to the control wells.
Plate Uniformity and Replication of Potency Measurements
Validation of the cAMP and high-content-based internalization assays for high-throughput screening (HTS) was performed according to the "Assay Guidance Manual " by Eli Lilly and the NIH Chemical Genomics Center. 22 Twoday plate uniformity studies with an interleaved signal format alternating high, medium, and low signals (see below) were performed.
The plate uniformity assessment for the cAMP antagonist assay was performed with three plates per day with interleaved high (CXCL12 + forskolin at the respective EC 80 concentrations), medium (CXCL12 + forskolin at the respective EC 80 concentrations + AMD3100 at the IC 50 concentration), and low (forskolin at the EC 80 concentrations) signals, with high and low signals representing negative and positive assay control, respectively.
The plate uniformity assessment for the high-content antagonist assay was performed with two plates per day with interleaved high (CXCL12 at the EC 80 concentration), medium (CXCL12 at the EC 80 concentration + AMD3100 at the IC 50 concentration), and low (DMSO) signals, with high and low signals representing negative and positive assay control, respectively.
The Z' factor 23 was calculated using the following formula: 
where Y is the response; [X] is the concentration; Top and Bottom are the upper and lower asymptotes, respectively; and EC 50 is the midpoint location (potency) parameter.
Screening data were analyzed using the XLfit 4 data management system (ID Business Solutions, Guildford, UK).
Results
Development of a Screening Assay Panel for the Identification of CXCR4 Antagonists
With the aim of finding CXCR4 antagonists, a highthroughput cAMP assay based on time-resolved fluorescence was implemented in a 384-well plate format with frozen recombinant CHO cells expressing CXCR4. In this immune-competition assay, the recombinant CXCR4expressing cells were first incubated with the test compounds in the presence of CXCL12 (for the antagonist assay), and then intracellular cAMP levels were measured through the inhibition of the energy transfer occurring between an anti-cAMP antibody labeled with europium cryptate and cAMP labeled with the dye d2, which were both added after the cell lysis. The energy transfer is inversely proportional to the intracellular cAMP concentration and is measured at 665 nm. The anti-cAMP cryptatelabeled antibody evokes a stable signal at 620 nm. The calculation of the HTRF ratio (665 nm/620 nm) eliminates possible compound interference. All the reactions were performed in the presence of the adenylyl cyclase activator forskolin at EC 80 and 0.5 mM of the phosphodiesterase inhibitor IBMX to increase the basal cAMP levels in each sample. To validate the assay, we tested the CXCL12 agonist and CXCL12 plus AMD3100 antagonist at first, both in concentration-response experiments (data not shown); as expected, the HTRF signal ratio increased as a result of Gα i -coupled CXCR4 activation by CXCL12, as compared to forskolin-stimulated cells, with an agonist potency ranging between 0.3 and 0.6 nM, which is in agreement with the reported value. 13 The preincubation with the reference antagonist AMD3100 inhibited the agonist response with a potency of 0.5-0.7 µM, which is comparable with the reported activity in the Ca 2+ flux assay. 25 In parallel, we developed a counterscreen consisting of a cAMP assay on wild-type CHO cells. We wished to verify whether the increase in cAMP levels determined by the putative CXCR4 antagonists was specifically due to prevention of CXCL12 action on the CXCR4 receptor or whether it was an unspecific off-target effect detectable also in the absence of CXCR4. To have a counterassay as representative as possible of the screening situation, we decided to set the following conditions: the basal signal, taken as negative control, corresponded to the one obtained by forskolin alone applied at its EC 20 concentration (data not shown) and was comparable to the one produced by the negative control of the functional assay (agonist at EC 80 plus forskolin at EC 80 ). Compound tests occurred under this mild forskolin stimulation. The treatment with forskolin alone at its EC 80 concentration was the positive control and represented the signal expected for a compound that unspecifically enhanced cAMP levels. Moreover, the applied conditions provided optimal sensitivity to small variations of the second messenger because the signal window between negative and positive controls matched the linear part of the standard curve of the HTRF assay. During the development of the screening assay, we demonstrated that neither agonist activity nor AMD3100-mediated signal inhibition could be observed on forskolin-treated cells (data not shown).
To verify the relevance of the CXCR4 recombinant model, the cAMP assay was performed in parallel in a disease-relevant cancer cell line with a high level of surface receptor. Given the reported CXCR4 implication in glioblastoma 6 and our specific interest in that disease area, we decided to perform the experiments with a neurosphereforming cell line (GBMR16) derived from a patient with recurrent glioblastoma multiforme (GBM). We selected this particular cell line from a series of commercially derived and patient-derived glioblastoma cell lines for the high CXCR4 membrane expression determined by FACS analysis (data not shown). Only GBMR16 neurosphere-forming cells showed a high level of CXCR4 (90% of positive cells) compared to the GBMR16 adherent subpopulation (Fig. 1,  left panels) . To analyze the functionality of the endogenous receptor, we tested the ability of CXCL12 to modulate intracellular cAMP levels. As shown in Fig. 1 (right panels) , the functional response well correlated with the presence of the receptor; we finally compared the activity of CXCL12 and two CXCR4 antagonists on glioblastoma versus recombinant CHO-CXCR4 cells. We observed that all the compounds showed a comparable activity in the two cellular models (Suppl. Fig. 1) .
To investigate β-arrestin recruitment by activated CXCR4, an enzyme-fragment complementation (EFC) assay was set up. We used a commercially available recombinant cell line in which the fusion protein of CXCR4 receptor and the small β-galactosidase ProLink™ fragment is coexpressed with the fusion protein of β-arrestin and the larger N-terminal fragment of β-galactosidase. To validate the assay, we tested the CXCL12 agonist and CXCL12 plus AMD3100 antagonist in concentration-response experiments; the recruitment of β-arrestin induced by CXCL12 elicited the luminescence signal by restoring a functional β-galactosidase enzyme ( Fig. 2A) . AMD3100 showed a partial agonist activity when tested alone ( Fig. 2A, inset) and acted as an antagonist in the presence of CXCL12. 16 The compound showed no activity in the β-galactosidase counterassay (Fig. 2B) .
We were also interested to see if any of the antagonist compounds could block internalization of the activated CXCR4 receptor, if some compounds could cause internalization, and if this process was always dependent on β-arrestin receptor binding. We therefore developed an additional secondary assay by combining high-content analysis and the SNAP-tag™ technologies. A recombinant In the antagonist assay, the compound was tested in the presence of CXCL12 at the EC 80 concentration (60 nM), and data were normalized between CXCL12-treated cells (100%) and DMSO control cells (0%); the related EC 50 and IC 50 values are reported in the figure. Besides the strong activity as a CXCL12 antagonist, AMD3100 also showed a slight activity as a partial agonist (A, inset). In contrast, no activity for AMD3100 was detected in the β-galactosidase counterassay. The error bars indicate the standard deviation of three replicates. U2OS cell line overexpressing the SNAP-CXCR4 fusion protein was generated. To exclude the possibility that the SNAP-tag could somehow affect CXCR4 folding and activity, the functionality of the SNAP-CXCR4 receptor was compared to the unmodified receptor in overexpressing CHO-CXCR4 cells using the above-described cAMP assay. Both cell lines showed a similar response to CXCL12 treatment (Fig. 3A) , indicating that the signaling capacity of the CXCR4 fusion protein was not compromised. The labeling of the SNAP-CXCR4 fusion protein with the impermeable benzylguanine SNAP-surface549 allowed receptor tracking by fluorescence microscopy. In nonstimulated cells, SNAP-CXCR4 was mainly localized onto the cell surface (Fig. 3C) ; on agonist stimulation, the receptor internalized, causing an increase of the intracellular granularity levels (Fig. 3B-D) . Agonist-induced receptor internalization was counteracted by the preincubation with the antagonist AMD3100 ( Fig. 3B-E) .
Assay Validation with Reference Antagonists
In addition to AMD3100, four CXCR4 reference antagonists (T140, FC131, CTCE-9908, and PMA) were profiled in the described assay panel to further validate each recombinant system and assay setup. Compound IC 50 and EC 50 values are reported in Table 1 . T140, FC131, and AMD3100 show antagonist activity in all the readouts. FC131 and T140 turned out to be the most potent compounds with IC 50 in the low nanomolar range, matching the reported potency values, 20 except for T140 in the β-arrestin recruitment assay, in which it showed a 100-fold higher IC 50 . In contrast, CTCE-9908 showed significantly less potency (15 µM) and only partial efficacy in all the readouts. PMA was a very potent antagonist in the G protein-dependent cAMP modulation and an equally potent agonist in both the G protein-independent pathways, and so represents a functional antagonist acting by sequestering the surface receptor from the agonist binding. 21 All compounds were inactive when tested in cAMP or β-galactosidase counterassays (data not shown).
Assay Robustness for HTS and SAR Analysis
To further validate the cAMP and internalization assays for HTS, we performed a 2-day plate uniformity assessment (Suppl. Fig. 2A-B) . The Z' values calculated for these assays were always higher than 0.4 in each plate, without obvious edge effects. The data analysis showed significant separation between the controls for both assays.
The reproducibility of potency measurements was also evaluated; the calculated minimum significant ratio (MSR) for each assay was <3 (data not shown).
Taken together, these results indicate that the two assays can produce high-quality and reproducible data.
Compound Screening and Profiling
We tested an internal library of 30,000 compounds at 10 µM in the HTRF cAMP assay. Forskolin-treated cells stimulated or not with CXCL12 at its EC 80 were considered as the negative (100%) and positive (0%) controls, respectively. By setting an activity threshold of 50% and a compound interference cutoff between 80% and 120% of the negative control, 539 active compounds were selected and retested under the same experimental conditions for confirmation. The 326 confirmed active compounds were then tested in a cAMP counterassay with wild-type CHO cells. Data were normalized on forskolin-treated cells at the EC 80 (0%) and EC 20 concentrations (100%), miming the agonist effect. Compounds significantly inhibiting the HTRF signal (threshold of 70%) were considered as being unspecific and were discarded. Concentration-response experiments were then performed on active and CXCR4-specific compounds to determine the IC 50 values.
Among the 284 CXCR4 antagonists with sufficient potency in the Gα i -protein-dependent cAMP modulation assay, 41 molecules from the most promising chemical clusters, when tested in the other two assay readouts as agonists or antagonists, showed the pathway selective profiles reported in Figure 4 . Among the eight compounds not affecting the β-arrestin recruitment, two showed agonist activity in CXCR4 internalization and six were inactive. Among the 33 compound antagonists in the β-arrestin recruitment assay, four turned out to be antagonists of receptor internalization, 11 were agonists (functional antagonists), and 18 were inactive. Whenever active, the compounds tested showed comparable potency values (in the low micromolar range) in the different readouts. Table  2 shows representative examples of compounds from the five groups. Concentration response curves in the different assays are shown in Supplemental Figure 3 .
Discussion
Targeting the CXCL12-CXCR4 axis is a promising avenue in cancer treatment, and preclinical evidence in support of the beneficial effects of such a strategy has been provided by blocking the ligand-receptor interaction with neutralizing antibodies, 7 peptides, 18, 19 or small molecules. 9 An extended inhibition of CXCR4 signaling has, however, been shown to be toxic, 26 which could be expected, given the multiple homeostatic functions of CXCR4 in maintaining hematopoietic stem cells in the bone marrow or in the lymphocyte trafficking. 3 These essential roles of CXCR4 may limit the therapeutic application of compounds that inhibit all CXCR4-signaling functions. CXCR4 signaling seems to differ in cancer and in healthy cells. It was reported for astrocytoma, 9 melanoma, and neuroblastoma cells 27 that CXCR4-mediated tumor-promoting effects, such as the enhancement of cell survival and growth, were apparent only in the malignant cells but not in the normal tissue cell background. The different behavior can be at least partially explained by an increase in receptor expression in the malignant cells. Because, however, under normal conditions excessive CXCR4 signaling is stringently counterregulated, it was therefore hypothesized that, in parallel to receptor upregulation, a dysregulation of CXCR4 signaling is responsible for novel biological effects in the malignant cells when compared to normal cells. Given the multiple effects evoked by CXCR4 downstream pathways, a correction of the abnormal signaling via pathway selective antagonists, rather than a complete inhibition, should provide improved therapeutic effect with a lower risk of toxicity. 8 With this aim in mind, we developed a panel of three CXCR4 functional assays to investigate the activity of compounds on three distinctive cellular events, namely, on Gα i -protein-dependent signaling (cAMP assay), G protein-independent signaling (β-arrestin assay), and receptor internalization (HCS assay). Although all assays were based on recombinant cells overexpressing CXCR4, we also performed the cAMP assay with a diseaserelevant system by using primary glioblastoma-derived neurospheres, which naturally express high levels of CXCR4 in the membrane. When we tested the endogenous ligand CXCL12 and the two reference compounds AMD3100 and CTCE-9908 in the two cell systems, we obtained similar results in terms of agonist and antagonist efficacy and range of compound potency. This observation suggests that the results obtained in the recombinant system could be reproduced in a human pathological context in which the receptor under investigation is endogenously expressed. We first tested four reported CXCR4 antagonists in our assay systems, specifically the approved small-molecule drug AMD3100 and the three peptides T140, FC131, and CTCE-9908. In addition, we also tested PMA, which, among other effects, is also reported to be a functional antagonist of CXCR4. 28 All reported CXCR4 antagonists were shown to be non-pathway-selective antagonists. In contrast, PMA acted as a potent agonist in the internalization assay while exhibiting a comparable antagonistic potency in the cAMP assay. This can be explained by the effect of PMA in sequestering the CXCR4 receptor from binding to CXCL12. In contrast to previous reports, 28 in our assay PMA acted as a potent β-arrestin recruiting agonist.
When we tested a series of 41 hit compounds derived from the screening of a 30,000-compound library in the cAMP primary assay, followed by characterization of selected compounds in the β-arrestin and internalization assays, five different profiles of CXCR4 antagonism were revealed: functional CXCR4 antagonists, which induced receptor internalization without affecting β-arrestin recruitment (profile 1); selective G protein-dependent antagonists (profile 2); full antagonists, such as the reference compounds (profile 4); antagonists for both G protein-dependent pathways and β-arrestin recruitment, which either promoted (profile 3) or did not affect CXCL12-mediated receptor internalization (profile 5). The pathway-selective profiles identified can be due to a selective induction of different functional and conformational states of the receptor by the different CXCR4 antagonists. In particular, apparent discrepancies between the effect on β-arrestin translocation and receptor internalization seen for some compounds can be read by considering the multiple molecular mechanisms underlying arrestin-dependent and -independent internalization of GPCRs 29 and assuming that different chemical scaffolds can favor one or the other mechanism. Given the known ability of surface CXCR4 to homo-and heterodimerize and the conformational change effect on the dimers induced by CXCL12 and reference antagonist binding, 30 the activity of our pathway-selective hits shall also be further investigated by monitoring their effect on receptor dimerization. Proceeding with compound characterization, the examination of these compounds in the human pathological context of primary glioblastoma-derived neurospheres, endogenously expressing the CXCR4 receptor, would enrich the framework of the activity and specificity of the hit compounds shown. Once pharmacologically validated with the above-mentioned assays as well as with receptorbinding studies and ERK phosphorylation evaluation, these molecules could represent valuable starting points for the development of lead molecules that are able to evoke different downstream effects on CXCR4-expressing cells, with a preference for pathway-selective CXCR4 antagonists that would offer therapeutic advantage over the nonselective compounds. In conclusion, our assay panel offered the advantage of combining different high-throughput technologies to provide a valuable approach to the early classification of different antagonism modes from the hit-identification phase of a screening cascade, thus allowing including pathway-selectivity data in hit selection and SAR analysis.
